%0 Journal Article
%T Type 1 diabetes mellitus following SARS-CoV-2 mRNA vaccination.
%A Aydoğan Bİ
%A Ünlütürk U
%A Cesur M
%A Aydoğan Bİ
%A Ünlütürk U
%A Cesur M
%J Endocrine
%V 78
%N 1
%D Oct 2022
%M 35809159
%F 3.925
%R 10.1007/s12020-022-03130-8
%X <B>OBJECTIVE: </B>Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccines have been reported to trigger immune side effects. Type 1 diabetes as a manifestation of autoimmune/inflammatory syndrome induced by adjuvants has been reported in a limited number of cases after vaccinations. A few type 1 diabetes cases after SARS-CoV-2 vaccination have been reported. This study aims to report type 1 diabetes cases associated with the mRNA-based SARS-CoV-2 vaccination.<BR><B>METHODS: </B>We report four cases of type 1 diabetes mellitus after mRNA-based SARS-CoV-2 vaccine, BNT162b2 (Pfizer-BioNTech). In the medical history, one subject had autoimmune thyroid disease. All patients had autoantibodies against glutamate decarboxylase.<BR><B>RESULTS: </B>In the presented case series, type 1 diabetes developed a few weeks after BNT162b2 vaccination. After developing type 1 diabetes, the insulin dose requirements of all patients decreased rapidly, and the need for insulin therapy in three patients disappeared during follow-up. Acute deterioration of glucose regulation in a patient followed by BNT162b2 administration may be due to vaccine-induced autoimmune diabetes.<BR><B>CONCLUSIONS: </B>Vaccination with BNT162b2 may trigger type 1 diabetes.